Abatacept as salvage therapy in chronic graft-versus-host disease—a retrospective analysis

URN to cite this document:: urn:nbn:de:bvb:355-epub-527186
DOI to cite this document:: 10.5283/epub.52718

Wertheimer, Tobias

; Dohse, Marius ; Afram, Gabriel ; Weber, Daniela ; Heidenreich, Martin ; Holler, Barbara ; Kattner, Anna-Sophia ; Neubauer, Andreas ; Mielke, Stephan ; Ljungman, Per ; Holler, Ernst ; Herr, Wolfgang ; Edinger, Matthias ; Martínez, Antonio Pérez ; Fante, Matthias ; Wolff, Daniel

License: Creative Commons Attribution 4.0
PDF - Published Version
(520kB)

Date of publication of this fulltext: 05 Aug 2022 06:27

Alternative links to fulltext:DOI Publisher

This publication is part of the DEAL contract with Springer.

Details

Preview

Indexed in

Export bibliographical data

Abstract

The immunomodulatory fusion protein abatacept has recently been investigated for the treatment of steroid-refractory chronic graft-versus-host disease (cGvHD) in a phase 1 clinical trial. We analyzed the safety and efficacy of abatacept for cGvHD therapy in a retrospective study with 15 patients who underwent allogeneic hematopoietic stem cell transplantation (allo-HSCT) and received abatacept ...